SCHEMBL2806795

SCHEMBL2806795

c1ccc(SSSSSc2ccccc2)cc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 3/20 0.69
HSD17B10 Q99714 2/20 0.69
MAPT P10636 1/20 0.69
SMN1; SMN2 Q16637 1/20 0.69
MGLL Q99685 1/20 0.69
ALDH1A1 P00352 5/20 0.43
MAPK1 P28482 1/20 0.43
FFAR1 O14842 1/20 0.35
MAOA P21397 2/20 0.33
MAOB P27338 2/20 0.33
TUBB4A P04350 1/20 0.33
TUBB P07437 1/20 0.33
TUBA3C P0DPH7 1/20 0.33
TUBA1B P68363 1/20 0.33
TUBA4A P68366 1/20 0.33
TUBB4B P68371 1/20 0.33
TUBB3 Q13509 1/20 0.33
TUBB2A Q13885 1/20 0.33
TUBB8 Q3ZCM7 1/20 0.33
TUBA3E Q6PEY2 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11325155 1.00 HPGD (0.69) HPGDHSD17B10MAPTSMN1; SMN2MGLL
SCHEMBL11313468 1.00 HPGD (0.69) HPGDHSD17B10MAPTSMN1; SMN2MGLL
SCHEMBL11320379 1.00 HPGD (0.69) HPGDHSD17B10MAPTSMN1; SMN2MGLL
SCHEMBL11316814 1.00 HPGD (0.69) HPGDHSD17B10MAPTSMN1; SMN2MGLL
SCHEMBL11328198 1.00 HPGD (0.69) HPGDHSD17B10MAPTSMN1; SMN2MGLL
SCHEMBL1253222 0.97 HPGD (0.73) HPGDHSD17B10MAPTSMN1; SMN2MGLL
SCHEMBL2802984 0.90 HPGD (0.73) HPGDHSD17B10MAPTSMN1; SMN2MGLL
SCHEMBL21508951 0.84 MAPT (0.50) HPGDHSD17B10MAPTSMN1; SMN2MGLL
SCHEMBL7759264 0.82 HPGD (1.00) HPGDHSD17B10MAPTSMN1; SMN2MGLL
SCHEMBL5148 0.82 HPGD (1.00) HPGDHSD17B10MAPTSMN1; SMN2MGLL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8202997-B2 Compositions and methods for treating or preventing hypoxic or ischemic injury IKARIA, INC. (US) 2012-06-19 US disclosed
US-8202997-B2 Compositions and methods for treating or preventing hypoxic or ischemic injury IKARIA, INC. (US) 2012-06-19 US disclosed
US-8202997-B2 Compositions and methods for treating or preventing hypoxic or ischemic injury IKARIA, INC. (US) 2012-06-19 US disclosed
US-20100130555-A1 COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING HYPOXIC OR ISCHEMIC INJURY IKARIA, INC. (US) 2010-05-27 US disclosed
US-20100130555-A1 COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING HYPOXIC OR ISCHEMIC INJURY IKARIA, INC. (US) 2010-05-27 US disclosed
US-20100130555-A1 COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING HYPOXIC OR ISCHEMIC INJURY IKARIA, INC. (US) 2010-05-27 US disclosed
WO-2010045582-A2 COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING HYPOXIC OR ISCHEMIC INJURY IKARIA, INC. (US) 2010-04-22 WO disclosed
US-4303765-A PEPTIZATION WITH AROMATIC POLYSULFIDE BAYER AKTIENGESELLSCHAFT (DE) 1981-12-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100130555-A1 COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING HYPOXIC OR ISCHEMIC INJURY HIF1AN, HIF1A, HYOU1 HPGD 26/4885HSD17B10 2133/4885MAPT 4528/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.